Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,343.72
(
-0.39%
)
US TECH 100
22,507.60
(
0.79%
)
Dow Jones
45,216.14
(
0.11%
)
Brent Oil
107.48
(
-1.01%
)
Bitcoin
66,349.80
(
-0.53%
)
News Focus
News Focus
Post# of 257314
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

rkrw

Send PM Follow Ignore
Followers 45
Posts 3206
Boards Moderated 0
Alias Born 12/29/2003

rkrw

Member Level

Re: genisi post# 84494

Sunday, 10/04/2009 9:48:08 AM

Sunday, October 04, 2009 9:48:08 AM

Post# of 257314
Talecris also is facing a future threat in baxter's pivotal study for a 1/monthly, 1 injection site of IGIV. Versus the talecris injectable which is once/week with several injection sites and poor bioavailability, so higher doses needed. IGIV is Talecris's biggest product.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today